The Latest Analyst Coverage For Zoetis Inc. (ZTS), Laboratory Corporation of America Holdings (LH)

Zoetis Inc. (NYSE:ZTS) shares were trading lower by -0.21 percent ($-0.15) at $71.39 a piece in Tuesday’s session. It had closed the previous session at $71.54. ZTS trades with a P/S ratio of 6.81. This compares with the industry’s 3.94 and the wider sector’s 5.42. A low price-to-sales ratio, typically less than 1.0, is considered a good value. Also, it has an estimated price-earnings (P/E) multiple of 26.25 and a trailing 12-month price-earnings (P/E) multiple of 37.65. Shares of ZTS have uptrended 16.08% in the past three months, while the S&P 500 has moved 9.23% in that time. Zoetis Inc. (ZTS) has a market cap of $34.92 billion and over the last 12 months, Zoetis Inc. (NYSE:ZTS) has gone stronger by 42.35%. During the last 52 weeks, the (NYSE:ZTS) price has been as high as $72.14 and as low as $48.54. Zoetis Inc. earnings have risen with an annualized rate of 27.5% over the last 5 years.

Zoetis Inc. (Mean Target Price: $71.83)

The average 1-year price target for Zoetis Inc. (ZTS) — averaging the work of different analysts — reveals a mean PT of $71.83/share. That’s a potential 0.62 increase relative to where Zoetis Inc. (NYSE:ZTS) has been trading recently. The current price is seen ranging between $71.26 and $71.63. There are brokerage firms with lower targets than the average, including one setting a price target of $57. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $82.

Zoetis Inc. (ZTS) Consensus Recommendation

The collective rating of 2 for Zoetis Inc. (NYSE:ZTS) also leans strongly towards the neutral end of the spectrum. Of the 21 analysts surveyed by Reuters that track ZTS 7 of them rate its stock a hold. The other 14, though not evenly; between analysts who think you should buy Zoetis Inc. versus those who think you should sell it. A 14 analysts rate it as either a buy or a strong buy, while0 believe that investors should either steer clear of ZTS or, if they already own its stock, sell it.

Is Laboratory Corporation of America Holdings (NYSE:LH) Cheap From Peers?

Laboratory Corporation of America Holdings (LH) knifed -0.22 percent lower and now trades for $151.22. LH comes in with a P/S ratio of 1.55 that’s greater than 1, potentially implying that it could be expensive relative to the overall sector (5.42) and its peers (12.89). Also, it has an estimated price-earnings (P/E) multiple of 14.65 and a trailing 12-month price-earnings (P/E) multiple of 21.1. During the last 52 weeks, the price has been as high as $164.22 and as low as $123.36. Laboratory Corporation of America Holdings (NYSE:LH) earnings have risen with a quarterly rate of 11.7% over the last 5 years. Shares of LH have sank -1.09% in the past three monthswhile the S&P 500 has dropped -7.07% in that time.

Laboratory Corporation of America Holdings (Price Objective: $171.94)

Laboratory Corporation of America Holdings (NYSE:LH) has a market cap of $15.57 billion and over the last 12 months, LH has risen by 20.29%. The average 1-year price target for (LH) reveals an average price target of $171.94 per share. That’s a potential 13.7 gain from where (NYSE:LH) has been trading recently. There are brokerage firms with lower targets than the average, including one setting a price target of $150. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $190.

Analyst Thoughts About Laboratory Corporation of America Holdings (NYSE:LH)

The consensus recommendation — averaging the work of 19 analysts — of 2.2 for Laboratory Corporation of America Holdings (LH) points to moderate case. Of the analysts surveyed by Reuters that track Laboratory Corporation of America Holdings 6 of them rate its stock a hold. The other 13 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. A 13 analysts rate it as either a buy or a strong buy, while 0 believe that investors should either steer clear of (NYSE:LH) or, if they already own its stock, sell it.